Latanoprost
Generic name
Latanoprost
Brand name
ATC Code
S01EE01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Compared to adults, the systemic exposure to the free acid of latanoprost was approximately twice as high in children aged 3 to < 12 years and six times as high in children < 3 years old, but this is still well within the safety margin in view of the occurrence of systemic side effects. The median time to peak plasma concentration was 5 minutes after dosing in all age groups. The median elimination half-life from the plasma was short (< 20 minutes) and similar in both paediatric and adult patients; it did not result in accumulation of the free acid of latanoprost in the systemic circulation under steady state conditions. (source: SPC)
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Reduction of intraocular pressure (in for example glaucoma) |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Transient redness and irritation, hypertrichosis of the lashes, increased pigmentation of the iris and lashes, possible sleep disorders. Colds and fever are side effects that occur more often in children than in adults.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Efficacy and safety data in the age group <1 year old (4 patients) are very limited. No data are available for premature babies (less than 36 weeks gestational age). In children 0 to <3 years of age who mainly suffer from primary congenital glaucoma (PCG), surgery (eg trabeculotomy / goniotomy) remains the treatment of choice. Long-term safety in children has not yet been established.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Parasympathomimetics | ||
|---|---|---|
| S01EB01 | ||
| Carbonic anhydrase inhibitors | ||
|---|---|---|
| S01EC01 | ||
| S01EC03 | ||
| Beta blocking agents | ||
|---|---|---|
| S01ED01 | ||
| Prostaglandin analogues | ||
|---|---|---|
| S01EE03 | ||
| S01EE04 | ||
| Other antiglaucoma preparations | ||
|---|---|---|
| S01EX | ||
| OTHER ANTIGLAUCOMA PREPARATIONS | ||
|---|---|---|
| S01EX | ||
References
- Black AC, et al, Latanoprost in pediatric glaucoma--pediatric exposure over a decade, J AAPOS, 2009, Dec;13(6), 558-62
- Elgin U, et al, The comparison of eyelash lengthening effect of latanoprost therapy in adults and children, Eur J Ophthalmol, 2006, Mar-Apr;16(2), 247-50
- Pfizer BV, SPC Xalatan (RVG 21304) 31-03-2022, www.geneesmiddeleninformatiebank.nl
- Enyedi LB, et al, Latanoprost for the treatment of pediatric glaucoma, Surv Ophthalmol, 2002, Aug;47 Suppl 1, S129-32
- Enyedi LB, et al, The effectiveness of latanoprost for the treatment of pediatric glaucoma, J AAPOS, 1999, Feb;3(1), 33-9
Changes
Therapeutic Drug Monitoring
Overdose
